Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
Aim. An overview of current pharmacotherapy for non-alcoholic steatohepatitis (NASH)-associated liver fibrosis.Key points. In current clinical recommendations, therapeutic measures in non-alcoholic fatty liver disease should include lifestyle change, body weight normalisation, NASH-associated liver...
| 發表在: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
|---|---|
| 主要作者: | |
| 格式: | Article |
| 語言: | 俄语 |
| 出版: |
Gastro LLC
2022-01-01
|
| 主題: | |
| 在線閱讀: | https://www.gastro-j.ru/jour/article/view/646 |